Results 101 to 110 of about 908,554 (203)
, 2022 personBACKGROUND: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies
Cavaco, Branca Maria +7 more
core +1 more source
Precision medicine in cutaneous melanoma—A comprehensive review
Journal of the European Academy of Dermatology and Venereology, EarlyView.Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley +1 more source
Molecular Oncology, 2022 Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer.
Rafal Dziadziuszko +15 more
doaj +1 more source
Tumour-agnostic drugs in paediatric cancers. [PDF]
, 2021 The recognition that new cancer drugs can be truly tumour-agnostic based on mechanism-of-action is important for paediatric cancers, where access to novel targeted therapies developed for adult indications has sometimes been problematic.
Carceller, F, Chisholm, JC, Marshall, LV
core +2 more sources
Histopathology, Volume 88, Issue 4, Page 747-768, March 2026.Invasive breast carcinomas with papillary features (IBCP) comprise diverse subtypes with variable architecture, histopathology, and clinical behaviour. This review outlines evolving classification, diagnostic criteria, and treatment implications, highlighting challenges in distinguishing in situ from invasive lesions. Standardised diagnostic approaches
Emad A Rakha +2 more
wiley +1 more source
Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
Clinical Case Reports, 2021 Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.
Catherine Percy +4 more
doaj +1 more source
Molecular determinants of signal transduction in tropomyosin receptor kinases
FEBS Open Bio, Volume 16, Issue 2, Page 252-267, February 2026.Tropomyosin receptor kinases control critical neuronal functions, but how do the same receptors produce diverse cellular responses? This review explores the structural mechanisms behind Trk signaling diversity, focusing on allosteric modulation and ligand bias.
Giray Enkavi
wiley +1 more source
gene amplification in patients with metastatic cancer [PDF]
Precision and Future Medicine, 2017 Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee +13 more
doaj +1 more source
A Giant Thoracic ALK‐Rearranged Mesenchymal Neoplasm in a Child
Cancer Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background Mesenchymal neoplasms characterized by ALK fusions mainly include inflammatory myofibroblastic tumors (IMTs) and epithelioid fibrous histiocytomas (EFHs). More recently, ALK‐rearranged mesenchymal tumors that are not IMTs or EFHs, characterized by S100 and CD34 coexpression, have been reported in a few small series and isolated case
Sheng Gao +9 more
wiley +1 more source
Diagnostic Pathology, 2021 Background Fusions of neurotrophic tropomyosin receptor kinase genes NTRK1, NTRK2 and NTRK3 with various partner genes occur in both common and rare tumours and are of paramount predictive value due to the availability of very effective pan-Trk ...
Florian Wagner +4 more
doaj +1 more source